Who are Beovu's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vabysmo, Vegf Trap, Macugen, Macugen, Avastin, Beovu.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/brolucizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Beovu — Competitive Intelligence Brief

Beovu (BROLUCIZUMAB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Metabolic.

marketed Vascular endothelial growth factor A Metabolic Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Beovu (BROLUCIZUMAB) — Novartis. Beovu works by binding to vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and reducing vascular permeability and inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Beovu TARGET	BROLUCIZUMAB	Novartis	marketed		Vascular endothelial growth factor A	2019-01-01
Vabysmo	FARICIMAB	Roche	marketed		Vascular endothelial growth factor A	2022-01-01
Vegf Trap	AFLIBERCEPT	Regeneron	marketed	Vascular Endothelial Growth Factor Inhibitor	Vascular endothelial growth factor A	2011-01-01
Macugen	EYE001	Valeant Pharms Llc	marketed		Vascular endothelial growth factor A	2004-01-01
Macugen	pegaptanib	Bausch Health	marketed		Vascular endothelial growth factor A	2004-01-01
Avastin	bevacizumab	Roche	marketed	Vascular Endothelial Growth Factor Inhibitor [EPC]	Vascular endothelial growth factor A	2004-01-01
Beovu	Beovu	Novartis Pharmaceuticals	marketed		Vascular endothelial growth factor A

Recent regulatory actions (last 90 days)

2026-04-09 — Vabysmo · FDA · approved · US · Roche

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Beovu — Competitive Intelligence Brief. https://druglandscape.com/ci/brolucizumab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab